🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchAmycretin (Novo Nordisk) — amylin/GLP-1 co-agonist Phase 1 data Page 2

Amycretin (Novo Nordisk) — amylin/GLP-1 co-agonist Phase 1 data

TrialNerd_Beth Tue, Jun 2, 2026 at 3:36 AM 9 replies 247 viewsPage 2 of 2
wendy_avl
Member
245
1,123
Oct 2024
Asheville, NC
Jun 2, 2026 at 4:43 AM#6

Adding the numbers, since they settle part of this. Say what you would expect to see if you were wrong, before you look. It is a small discipline and it changes what you notice.

Last edited: Jun 2, 2026 at 10:43 AM
4 7SleepFixSam, PurityPaulOR, MaxMetOK and 1 other
Reply Quote Save Share Report
PharmHunterJen
Member
567
2,345
Jul 2024
Illinois
Jun 2, 2026 at 5:09 AM#7

One thing that is still open after EndoResFellow’s answer:

What did you change at the same time, and can you separate the two now?

5 8alex_tucson, kevin_tulsa, Dr.PainCLE and 2 others
Reply Quote Save Share Report
Dr.GastroMayo
VIP Member
2,345
13,456
Jan 2024
Mayo Clinic, MN
Jun 2, 2026 at 5:35 AM#8
wendy_avl said:
Say what you would expect to see if you were wrong, before you look.

There is a second half to this that has not been said yet. The distinction that resolves most of these threads is between what is true on average and what is true for one person. Both are real; they answer different questions and get quoted as if they were the same one.

6 9COA_Karl, MikeFit_NJ, InsuranceTom and 3 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
TrialNerd_Beth
Senior Member
2,345
11,234
Jan 2024
Bethesda, MD
Jun 2, 2026 at 6:01 AM#9

Closing the loop on my own question.

Following up because I said I would. I changed one thing, left everything else alone, and waited the full interval before looking. It resolved, and I cannot prove which half of that did it.

7 10DoseLogDan, SleepFixSam, PurityPaulOR and 4 others
Reply Quote Save Share Report
RegAffairsDC
Member
678
3,456
May 2024
Washington, DC
Jun 2, 2026 at 8:06 AM#10
Dr.GastroMayo said:
The distinction that resolves most of these threads is between what is true on average and what is true for one person.

Agreed, and one caution: a single measurement is not a measurement. Anything that moves day to day needs a trend before it means anything at all.

I would rather be corrected than agreed with, if it comes to it.

45 20gary_naperville, sean_dublin, hannah_MT and 42 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register